XNYS · Healthcare · Drug Manufacturers - General
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | 0.23 | -0.13 | -156.52% | $16.61B | ❌ Miss | +0.16% | +1.89% | — |
| 2026-04-30 | Q1 2026 | -1.48 | -1.28 | +13.51% | $16.29B | ✅ Beat | -1.29% | +2.86% | +8.74% |
| 2026-02-03 |
| Q4 2025 |
| 2.02 |
| 2.04 |
| +0.99% |
| $16.40B |
| ✅ Beat |
| +0.12% |
| +1.13% |
| +0.20% |
| 2025-10-30 | Q3 2025 | 2.35 | 2.58 | +9.79% | $17.28B | ✅ Beat | — | — | — |
| 2025-07-29 | Q2 2025 | 2.01 | 2.13 | +5.97% | $15.81B | ✅ Beat | — | — | — |
| 2025-04-24 | Q1 2025 | 2.14 | 2.22 | +3.74% | $15.53B | ✅ Beat | — | — | — |
| 2025-02-04 | Q4 2024 | 1.68 | 1.72 | +2.38% | $15.62B | ✅ Beat | — | — | — |
| 2024-10-31 | Q3 2024 | 1.51 | 1.57 | +3.97% | $16.66B | ✅ Beat | — | — | — |
Showing last 8 quarters.